XOMA Royalty (XOMA) Return on Capital Employed (2011 - 2026)
XOMA Royalty's (XOMA) quarterly Return on Capital Employed came in at 0.11% in Q1 2026, up 1387.0% year-on-year from 0.01% in Q1 2025, and down 96.03% quarter-over-quarter from 2.87% in Q4 2025.
XOMA Royalty (XOMA) Return on Capital Employed (2011 - 2026) Analysis & Trends
XOMA Royalty has disclosed Return on Capital Employed across 16 years of filings, most recently posting 0.11% for Q1 2026.
- Return on Capital Employed for Q1 2026 came in at 0.11%, up 1387.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 0.11% (up 1387.0% YoY), and the FY2025 annual result was 3.15%, up 2280.0% from the prior year.
- Return on Capital Employed came in at 0.11% for Q1 2026 at XOMA Royalty, down from 2.87% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 14.13% in Q1 2022 to a low of 26.2% in Q4 2023.
- The 5-year median for Return on Capital Employed is 13.76% (2025), against an average of 9.65%.
- Across the five-year window, Return on Capital Employed plunged 3779 bps in 2023 and soared 2572 bps in 2025, its largest moves.
- XOMA Royalty's Return on Capital Employed stood at 12.76% in 2022, then tumbled by 105 bps to 26.2% in 2023, then rose by 23 bps to 20.2% in 2024, then soared by 114 bps to 2.87% in 2025, then tumbled by 96 bps to 0.11% in 2026.
- The last three Return on Capital Employed figures came in at 0.11% (Q1 2026), 2.87% (Q4 2025), and 0.91% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | 450.31% |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | 51.73% |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | -107.40% |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | -50.43% |
| 10 | XOMA Royalty | 5.52 Mn | -60.56 Mn | - | 0.11% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 0.11% |
| Dec 31, 2025 | 2.87% |
| Sep 30, 2025 | 0.91% |
| Jun 30, 2025 | -6.29% |
| Mar 31, 2025 | -13.76% |
| Dec 31, 2024 | -20.20% |
| Sep 30, 2024 | -24.82% |
| Jun 30, 2024 | -20.12% |
| Mar 31, 2024 | -18.30% |
| Dec 31, 2023 | -26.20% |
| Sep 30, 2023 | -24.55% |
| Jun 30, 2023 | -21.79% |
| Mar 31, 2023 | -20.10% |
| Dec 31, 2022 | -12.76% |
| Sep 30, 2022 | 13.24% |
| Jun 30, 2022 | 13.62% |
| Mar 31, 2022 | 14.13% |
| Dec 31, 2021 | 12.93% |
| Sep 30, 2021 | 8.72% |
| Jun 30, 2021 | 9.62% |